The collaboration with Sanofi focuses on developing bispecific antibodies for autoimmune diseases, leveraging predictive ...

On the heels of FDA’s approval of the Wegovy Pill, Novo Noridsk announced that the oral GLP-1 is now available to patients ...

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, ...

FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...

Hoth Therapeutics filed two provisional patent applications with the U.S. Patent and Trademark Office, expanding the ...

In 2024, AbbVie’s presentation at the conference focused on its recent acquisitions of ImmunoGen and Cerevel. AbbVie paid ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...

A. Douglas Bender is an associate professor of management in the School of Business Management of Widener University, Chester, PA, where he teaches graduate courses in managed care organizations and ...

Johnson & Johnson announced that management will hold a fireside chat at 11:15 am, Est, on Monday, January 12, 2026. It will also be presented as a live audio webcast on J&J’s investor relations site.

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...

Lou Pillai is the founder of Ulivmo and most recently, he was the Head of Data and Digital at Immunomedics (acquired by Gilead). Ehsan Ehsani is a director of consulting at CGI and leader of ...